Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 126

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 126
---
astem may fail to realize some or all of the anticipated benefits of the proposed Merger, which may adversely affect the value of each Kadimastem Ordinary Share. The success of the Merger will depend, in part, on Kadimastem’s ability to realize the anticipated benefits from combining Kadimastem and NLS. However, to realize these anticipated benefits, the businesses of Kadimastem and NLS must be successfully combined and the two companies’ respective operations, technologies and personnel must be integrated following the closing of the merger. If Kadimastem is not able to achieve these objectives within the anticipated time frame, or at all, the anticipated benefits and cost savings of the Merger may not be realized fully or at all or may take longer to realize than expected and the value of Kadimastem Ordinary Shares may be adversely 40 affected. In addition, the overall integration of the businesses is a complex, time -consumingand expensive process that, without proper planning and effective and timely implementation, could significantly disrupt Kadimastem’s operations following closing. Specifically, risks in integrating NLS into Kadimastem’s operations to realize the anticipated benefits of the Merger include, among other things, the failure to: •effectively coordinate efforts to communicate Kadimastem’s capabilities and products following closing; •compete effectively for additional opportunities expected to be available to Kadimastem following closing; •integrate and harmonize financial reporting and information technology systems of Kadimastem and NLS; •retain Kadimastem’s relationships with its customers and successfully integrate NLS into these existing relationships; •integrate NLS and Kadimastem executive officers’ teams; •retain and integrate key NLS and Kadimastem employees; •successfully address Kadimastem’s existing liabilities; •coordinate operations across time zones, continents and cultures; •manage the diversion of management’s attention from business matters to integration issues; •retain customers; and •combine Kadimastem’s business and management culture with the business and management culture of NLS. For more information, please see “ Summary of Risk Factors — Risks Related to the Merger” and “ Summary of Risk Factors — Risks Related to NLS After the Consummation of the Merger.” Risks Related to Product Development, Regulatory Approval and Commercialization Kadimastem depends substantially on the success of its proprietary product candidates. Kadimastem cannot give any assurance that any of its drug substances and product candidates will receive